Literature DB >> 25200940

Price regulation and relative delays in generic drug adoption.

Joan Costa-Font1, Alistair McGuire1, Nebibe Varol2.   

Abstract

Increasing the adoption of generic drugs has the potential to improve static efficiency in a health system without harming pharmaceutical innovation. However, very little is known about the timing of generic adoption and diffusion. No prior study has empirically examined the differential launch times of generics across a comprehensive set of markets, or more specifically the delays in country specific adoption of generics relative to the first country of (generic) adoption. Drawing on data containing significant country and product variation across a lengthy time period (1999-2008), we use duration analysis to examine relative delays, across countries, in the adoption of generic drugs. Our results suggest that price regulation has a significant effect on reducing the time to launch of generics, with faster adoption in higher priced markets. The latter result is dependent on the degree of competition and the expected market size.
Copyright © 2014 Elsevier B.V. All rights reserved.

Keywords:  Adoption; Duration analysis; Generic competition; Regulation

Mesh:

Substances:

Year:  2014        PMID: 25200940     DOI: 10.1016/j.jhealeco.2014.04.004

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  7 in total

1.  The diffusion of generics after patent expiry in Germany.

Authors:  Katharina Elisabeth Fischer; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2015-11-16

2.  A comparison of generic drug prices in seven European countries: a methodological analysis.

Authors:  Olivier J Wouters; Panos G Kanavos
Journal:  BMC Health Serv Res       Date:  2017-03-31       Impact factor: 2.655

3.  Is medicines parallel trade 'regulatory arbitrage'?

Authors:  Joan Costa-Font
Journal:  Int J Health Econ Manag       Date:  2016-09-23

4.  The Impact of Tiered-Pricing Framework on Generic Entry in Canada.

Authors:  Wei Zhang; Huiying Sun; Daphne P Guh; Larry D Lynd; Aidan Hollis; Paul Grootendorst; Aslam H Anis
Journal:  Int J Health Policy Manag       Date:  2022-06-01

5.  Biosimilars: How Can Payers Get Long-Term Savings?

Authors:  Jorge Mestre-Ferrandiz; Adrian Towse; Mikel Berdud
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

6.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

7.  Is greater generic competition also linked to lower drug prices in South Korea?

Authors:  Kyung-Bok Son
Journal:  Health Econ Rev       Date:  2020-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.